recombinant erythropoietin

Summary

Summary: ERYTHROPOIETIN prepared by recombinant DNA technology.

Top Publications

  1. pmc Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling
    Laura Calvillo
    Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
    Proc Natl Acad Sci U S A 100:4802-6. 2003
  2. ncbi Breast cancer trial with erythropoietin terminated unexpectedly
    Brian Leyland-Jones
    McGill University, Montreal, Canada
    Lancet Oncol 4:459-60. 2003
  3. ncbi Plant recombinant erythropoietin attenuates inflammatory kidney cell injury
    Andrew J Conley
    Department of Biology, University of Western Ontario, London, ON, Canada, N6A 5B7
    Plant Biotechnol J 7:183-99. 2009
  4. ncbi Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
    I C MacDougall
    Department of Renal Medicine, King s College Hospital, London, United Kingdom
    J Am Soc Nephrol 10:2392-5. 1999
  5. ncbi Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
    Julia Bohlius
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    Lancet 373:1532-42. 2009
  6. ncbi Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
    Michael Henke
    Abteilung Strahlenheilkunde der Radiologischen Universitätsklinik, Hugstetter Strasse 55, D 79106, Freiburg, Germany
    Lancet 362:1255-60. 2003
  7. ncbi Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure
    D W Johnson
    Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia
    Kidney Int 69:1806-13. 2006
  8. ncbi Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats
    Masanori Iwai
    Department of Neurology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15261, USA
    Stroke 38:2795-803. 2007
  9. pmc Recombinant erythropoietin in clinical practice
    T Ng
    Phase One Clinical Trials Unit Ltd, Plymouth, UK
    Postgrad Med J 79:367-76. 2003
  10. ncbi Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis
    Arintaya Phrommintikul
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
    Lancet 369:381-8. 2007

Detail Information

Publications251 found, 100 shown here

  1. pmc Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling
    Laura Calvillo
    Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
    Proc Natl Acad Sci U S A 100:4802-6. 2003
    ....
  2. ncbi Breast cancer trial with erythropoietin terminated unexpectedly
    Brian Leyland-Jones
    McGill University, Montreal, Canada
    Lancet Oncol 4:459-60. 2003
  3. ncbi Plant recombinant erythropoietin attenuates inflammatory kidney cell injury
    Andrew J Conley
    Department of Biology, University of Western Ontario, London, ON, Canada, N6A 5B7
    Plant Biotechnol J 7:183-99. 2009
    ..These findings demonstrate that tobacco plants may be an attractive alternative for the production of large amounts of biologically active EPO...
  4. ncbi Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
    I C MacDougall
    Department of Renal Medicine, King s College Hospital, London, United Kingdom
    J Am Soc Nephrol 10:2392-5. 1999
    ..The longer half-life of NESP is likely to confer a clinical advantage over Epoetin by allowing less frequent dosing in patients treated for anemia...
  5. ncbi Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
    Julia Bohlius
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    Lancet 373:1532-42. 2009
    ..We therefore did a meta-analysis of randomised controlled trials in which these drugs plus red blood cell transfusions were compared with transfusion alone for prophylaxis or treatment of anaemia in patients with cancer...
  6. ncbi Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
    Michael Henke
    Abteilung Strahlenheilkunde der Radiologischen Universitätsklinik, Hugstetter Strasse 55, D 79106, Freiburg, Germany
    Lancet 362:1255-60. 2003
    ..We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer...
  7. ncbi Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure
    D W Johnson
    Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia
    Kidney Int 69:1806-13. 2006
    Administration of human recombinant erythropoietin (EPO) at time of acute ischemic renal injury (IRI) inhibits apoptosis, enhances tubular epithelial regeneration, and promotes renal functional recovery...
  8. ncbi Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats
    Masanori Iwai
    Department of Neurology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15261, USA
    Stroke 38:2795-803. 2007
    ..The current study investigates the effects of exogenous administration of EPO on revascularization and neurogenesis, 2 major events thought to contribute to neuronal replacement, in the neonatal brain after hypoxia/ischemia (H/I)...
  9. pmc Recombinant erythropoietin in clinical practice
    T Ng
    Phase One Clinical Trials Unit Ltd, Plymouth, UK
    Postgrad Med J 79:367-76. 2003
    ..Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment...
  10. ncbi Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis
    Arintaya Phrommintikul
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
    Lancet 369:381-8. 2007
    ..Our aim was to determine whether targeting different haemoglobin concentrations with such treatment is associated with altered all-cause mortality and cardiovascular events in patients with anaemia caused by chronic kidney disease...
  11. ncbi Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus
    Sandra E Juul
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Pediatr Res 65:485-92. 2009
    ....
  12. ncbi Pure red-cell aplasia and epoetin therapy
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
    N Engl J Med 351:1403-8. 2004
    ....
  13. ncbi Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Tilman B Drueke
    Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
    N Engl J Med 355:2071-84. 2006
    ..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established...
  14. ncbi Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia
    Norifumi Urao
    Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto 602 8566, Japan
    Circ Res 98:1405-13. 2006
    ..In conclusion, Epo treatment inhibits the neointimal hyperplasia after arterial injury in an NO-dependent manner by acting on the injured vessels and mobilizing EPCs to the neo-endothelium...
  15. ncbi Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
    Nicole Casadevall
    Department of Hematology, Hotel Dieu, Paris, France
    N Engl J Med 346:469-75. 2002
    ..We investigated whether there was an immunologic basis for the anemia in these patients...
  16. ncbi Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure
    Francesco Locatelli
    Nephrol Dial Transplant 19:ii1-47. 2004
  17. ncbi Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin
    Ted Wun
    Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California 95817, USA
    Cancer 98:1514-20. 2003
    ..The authors performed a retrospective analysis to determine whether there was an increased rate of symptomatic venous thrombosis associated with the use of rHuEpo in patients with carcinoma of the uterine cervix and vagina...
  18. ncbi Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity
    J J Thomsen
    Copenhagen Muscle Research Centre, Rigshospitalet, Section 7652, 2100, Copenhagen Ø, Denmark
    Eur J Appl Physiol 101:481-6. 2007
    ..8% as compared to pre rHuEpo administration. In conclusion, in healthy non-athlete subjects rHuEpo administration prolongs submaximal exercise performance by about 54% independently of the approximately 12% increase in VO2max...
  19. ncbi Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise
    Gabrielle Russell
    Department of Physiology, Australian Institute of Sport, Canberra, Australia
    Eur J Appl Physiol 86:442-9. 2002
    The aim of this study was to characterise the effect of prolonged low doses of recombinant erythropoietin (r-HuEPO) on the responses to submaximal and maximal exercise...
  20. ncbi Iron therapy in the pediatric hemodialysis population
    Bradley A Warady
    Section of Pediatric Nephrology, Children s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
    Pediatr Nephrol 19:655-61. 2004
    ..In summary, although both oral and i.v. iron maintained patients in an iron-replete state in this short-term study, only i.v. therapy allowed for a significant improvement in iron stores...
  21. ncbi Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in rats
    Thomas Lieutaud
    Department Reanimation et Anesthesiologie, Hopital Neurologique, Hospices Civils de Lyon, Lyon, France
    J Neurotrauma 25:1179-85. 2008
    ..Further, it has biological efficacy at 8 h on several inflammatory proteins, yet must be employed at high doses to cross the BBB...
  22. pmc Neurorestorative treatment of stroke: cell and pharmacological approaches
    Jieli Chen
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan, USA
    NeuroRx 3:466-73. 2006
    ..Both the MSCs and the pharmacologic agents potentiate brain plasticity and neurobehavioral recovery after stroke...
  23. ncbi Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure
    Yiwen Li
    Second Department of Internal Medicine, Gifu University School of Medicine, 1 1 Yanagido, Gifu 501 1194, Japan
    Cardiovasc Res 71:684-94. 2006
    ..We investigated the mechanisms, including the downstream signaling pathways, for the beneficial effect of late treatment with EPO on chronic post-MI heart failure...
  24. ncbi Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts
    Sophie Pinel
    Laboratoire de Recherche en Oncologie, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Int J Radiat Oncol Biol Phys 59:250-9. 2004
    ..Furthermore, the consequences of rHuEPO administration on tumor response to fractionated radiotherapy (RT) were evaluated...
  25. ncbi Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models
    Jozsef Tovari
    Department of Tumor Progression and Central Laboratory, National Institute of Oncology, Budapest, Hungary
    Cancer Res 65:7186-93. 2005
    ....
  26. ncbi Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin
    Kimberly L Blackwell
    Division of Medical Oncology, Department of Medicine, Duke University Comprehensive Cancer Center, Erwin Road, Durham, NC 27710, USA
    Cancer Res 63:6162-5. 2003
    ..These data confirm that tumor oxygenation in nonanemic individuals may be improved through the administration of EPO, and this improvement appears to be independent of HgB effects...
  27. ncbi Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    J Natl Cancer Inst 97:489-98. 2005
    ..Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant diseases...
  28. ncbi Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells
    Cristobal Belda-Iniesta
    Translational Oncology Unit CSIC UAM, Medical Oncology Division, Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    Cancer Biol Ther 6:1600-5. 2007
    Human recombinant erythropoietin (hrEPO) therapy might be associated with tumor progression and death. This effect has been suggested to be secondary to rhEPO binding to its receptor (EPOR) expressed on cancer cells...
  29. ncbi Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods
    Diego F Ossa
    Oxford Outcomes Ltd, Oxford, UK
    Pharmacoeconomics 25:223-37. 2007
    ....
  30. ncbi Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia
    Keyvan Karkouti
    Toronto General Hospital, University Health Network, Department of Anesthesia, 3 Eaton North, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Can J Anaesth 53:11-9. 2006
    To determine if early recovery from severe post-operative anemia is accelerated by iv iron therapy alone or in combination with recombinant erythropoietin (EPO).
  31. ncbi An approach to using recombinant erythropoietin for neuroprotection in very preterm infants
    Jean Claude Fauchere
    Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland
    Pediatrics 122:375-82. 2008
    ..We investigated whether administration of high-dose recombinant human erythropoietin to very preterm infants shortly after birth and subsequently during the first 2 days is safe in terms of short-term outcome...
  32. ncbi A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats
    Brian A Kellert
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Pediatr Res 61:451-5. 2007
    ..rEpo provides dose-dependent neuroprotection. Of the regimens tested, three doses of 5,000 U/kg was optimal because it provided maximal benefit with limited total exposure...
  33. pmc Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume
    Carsten Lundby
    Copenhagen Muscle Research Center, Rigshospitalet section 7652, 2100 Copenhagen, Denmark
    J Physiol 578:309-14. 2007
    ..9 and 53.9% during the study period, this mechanism seems as important for increasing arterial oxygen content as the well-known erythropoietic effect of Epo...
  34. ncbi Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma
    James C Tsai
    Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, USA
    Curr Eye Res 30:1025-31. 2005
    ..The aim of this pilot study was to evaluate the potential neuroprotective effect of an intravitreal injection of erythropoietin (EPO) on retinal ganglion cell (RGC) preservation in an episcleral vessel cautery-induced rat model of glaucoma...
  35. ncbi Anemia, tumor hypoxemia, and the cancer patient
    John Varlotto
    Department of Radiation Oncology, Boston VA Medical Center, Boston, MA 02130, USA
    Int J Radiat Oncol Biol Phys 63:25-36. 2005
    ..To review the impact of anemia/tumor hypoxemia on the quality of life and survival in cancer patients, and to assess the problems associated with the correction of this difficulty...
  36. ncbi Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
    Charles L Bennett
    VA Chicago Healthcare System, Department of Medicine, Northwestern University Feinberg School of Medicine, and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    JAMA 299:914-24. 2008
    ..Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs...
  37. ncbi Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat
    Bruno Sepodes
    Faculty of Pharmacy, Unit of Pharmacology and Pharmacotoxicology, University of Lisbon, Av Forcas Armadas, Lisbon, Portugal
    Transpl Int 19:919-26. 2006
    ..Using a rat model of liver I/R injury, we aimed to determine the effect of the administration of human recombinant erythropoietin (rhEPO) on liver injury. Rats were subjected to 30 min of liver ischemia followed by 2 h of reperfusion...
  38. ncbi Erythropoietin is a multifunctional tissue-protective cytokine
    Serhat Erbayraktar
    The Kenneth S Warren Institute, 712 Kitchawan Road, Kitchawan, NY 10562, USA
    Curr Hematol Rep 2:465-70. 2003
    ..We review the evidence that EPO and its receptor function as a paracrine/autocrine system to mediate the protection of tissues subjected to metabolic stress...
  39. ncbi Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients
    Kazuhisa Miyashita
    Division of Nephrology, the Japanese Red Cross Medical Center, Tokyo, Japan
    Hypertens Res 27:79-84. 2004
    ..In conclusion, a single injection of rHuEPO increased blood pressure with a positive correlation with endothelin-1 release in hemodialysis patients, but not in predialysis chronic renal failure patients...
  40. ncbi Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration
    Lei Wang
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan 48202, USA
    J Neurosci 26:5996-6003. 2006
    ..These data demonstrate that activated endothelial cells can promote neural progenitor cell migration, and provide insight into the molecular mechanisms underlying the attraction of newly generated neurons to injured areas in brain...
  41. ncbi Erythropoietin regulates endothelial progenitor cells
    Ferdinand H Bahlmann
    Department of Internal Medicine, Hannover Medical School, Carl Neuberg Strasse 1, 30625, Hannover, Germany
    Blood 103:921-6. 2004
    ..Erythropoietin increases the number of functionally active EPCs in humans. Administration of rhEPO or EPO analogs may open new therapeutic strategies in regenerative cardiovascular medicine...
  42. ncbi Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
    Michael Henke
    Klinik fur Strahlenheilkunde, Universitatsklinikum, Robert Koch Strasse, 3 D 79106, Freiburg, Germany
    J Clin Oncol 24:4708-13. 2006
    ..Recent reports suggest that cancer control may worsen if erythropoietin is administered. We investigated whether erythropoietin receptor expression on cancer cells may correlate with this unexpected finding...
  43. ncbi Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis
    J P Kaltwasser
    Medizinische Klinik III, Bereich Rheumatologie, J W Goethe Universitat, Frankfurt Main, Germany
    J Rheumatol 28:2430-6. 2001
    ..v.) iron influences health related quality of life (HRQoL) and clinical outcome including disease activity...
  44. pmc Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
    M L Brines
    The Kenneth S Warren Laboratories, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 97:10526-31. 2000
    ..Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-Hu-EPO as a general neuroprotective treatment are warranted...
  45. ncbi Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
    Mol Cancer Ther 5:356-61. 2006
    ..Clinically, recombinant erythropoietin treatment of malignancy-related anemia has yet to be definitively associated with any modulation of ..
  46. pmc Effects of recombinant erythropoietin on breast cancer-initiating cells
    Tiffany M Phillips
    Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, 10833 LeConte Ave, Los Angeles, CA 90095 1714, USA
    Neoplasia 9:1122-9. 2007
    ..Cancer recurrence is thought to rely on the proliferation of cancer initiating cells (CICs). In breast cancer, CICs can be identified by phenotypic markers and their fate is controlled by the Notch pathway...
  47. ncbi Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress
    Jing Liu
    Department of Neurosurgery, Program in Neurosciences, Stanford University School of Medicine, California, USA
    Glia 53:360-5. 2006
    ..Our study demonstrates an important role for Epo in the protection of astrocytes from reactive oxygen species. We suggest that Epo can compensate in part for the antioxidant properties of mitochondrial SOD2 deficiency...
  48. pmc MRI identification of white matter reorganization enhanced by erythropoietin treatment in a rat model of focal ischemia
    Lian Li
    Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
    Stroke 40:936-41. 2009
    ....
  49. ncbi Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed
    Camilla Palumbo
    Department of Experimental Medicine and Biochemical Sciences, Universita degli Studi di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Cancer Chemother Pharmacol 61:893-901. 2008
    ..Human recombinant erythropoietin (rHuEpo) is currently used for the treatment of anemia in cancer patients...
  50. pmc Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia
    O Thews
    Institute of Physiology and Pathophysiology, Johannes Gutenberg University, Mainz, Germany
    Br J Cancer 78:752-6. 1998
    ..These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue...
  51. pmc Development and characterization of novel erythropoiesis stimulating protein (NESP)
    J C Egrie
    Amgen Inc, One Amgen Center Drive, MS 27 4 A, Thousand Oaks, CA 91320 1799, USA
    Br J Cancer 84:3-10. 2001
    ..NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence...
  52. ncbi Novel applications of recombinant erythropoietin
    Edward J Sharples
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
    Curr Opin Pharmacol 6:184-9. 2006
    b>Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erythroid precursors...
  53. ncbi Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes
    Dario Ferrero
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
    Br J Haematol 144:342-9. 2009
    The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with 'refractory anaemia' according to the World Health Organization (WHO)...
  54. ncbi Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps
    Michele Buemi
    Department of Internal Medicine, University of Messina, Italy
    Acta Derm Venereol 82:411-7. 2002
    ....
  55. ncbi Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients
    Abelardo Aguilera
    Servicio de Nefrologia, Hospitales Universitarios de la Princesa y la Paz, Madrid, Spain
    Adv Perit Dial 18:200-5. 2002
    ..By decreasing leptin, rHuEPO could increase food intake and improve the nutritional status of PD patients. At baseline, we confirm the existence of a chronic inflammatory process in uremia...
  56. ncbi Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants
    Seyedeh Fatemeh Khatami
    Tehran University of Medical Sciences, Tehran, Iran
    Indian J Pediatr 75:1227-30. 2008
    Early recombinant erythropoietin therapy and iron therapy would decrease the need for red blood cells transfusions and prevents anemia of prematurity.
  57. ncbi Effect of rhEPO administration on serum levels of sTfR and cycling performance
    K I Birkeland
    Hormone Laboratory, Aker University Hospital and Norwegian University of Sport and Physical Education, Oslo
    Med Sci Sports Exerc 32:1238-43. 2000
    We assessed the possibility of using soluble transferrin receptor (sTfR) as an indicator of doping with recombinant erythropoietin (rhEPO).
  58. ncbi Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial
    H Donato
    Clinical Research Area, Bio Sidus S A Laboratory, Buenos Aires, Argentina
    Pediatrics 105:1066-72. 2000
    ..We investigated whether early use of rHuEPO would reduce the total transfusion requirement and/or the number of transfusions throughout the first 2 weeks of life...
  59. ncbi Derivatives of erythropoietin that are tissue protective but not erythropoietic
    Marcel Leist
    H Lundbeck A S, 2500 Valby, Denmark
    Science 305:239-42. 2004
    ....
  60. pmc Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
    M E Hardee
    Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
    Br J Cancer 93:1350-5. 2005
    ..Improved tumour oxygenation should translate into increased treatment response. Exogenous recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model...
  61. ncbi The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants
    Gulcan Turker
    Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
    Am J Perinatol 22:449-55. 2005
    ..We suggest that r-Hu EPO combined with early enteral iron is both effective and safe in infants<1000 g...
  62. ncbi Pure red-cell aplasia and recombinant erythropoietin
    Sharon K Gershon
    N Engl J Med 346:1584-6; author reply 1584-6. 2002
  63. ncbi Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells
    Laurie Feldman
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Prostate 66:135-45. 2006
    ..EpoR have been identified on a variety of non-hematopoietic cells, both normal and malignant, however, little is known about the function of EpoR on malignant cells...
  64. ncbi Time and temperature dependant changes in red blood cell analytes used for testing recombinant erythropoietin abuse in sports
    Neil Robinson
    Laboratoire Suisse d Analyse du Dopage, Institut Universitaire de Medecine Legale, Lausanne, Switzerland
    Clin Lab 50:317-23. 2004
    ..the effect of temperature on the possible deterioration of red blood cell analytes used for testing recombinant erythropoietin abuse...
  65. pmc Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock
    F Squadrito
    Institute of Pharmacology, School of Medicine, University of Messina, Italy
    Br J Pharmacol 127:482-8. 1999
    ..Finally rh-EPO inhibited the activity of iNOS in peritoneal macrophages activated with endotoxin. 4. Our data suggest that rh-EPO protects against SAO shock by inhibiting iNOS activity...
  66. ncbi Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransferase expression
    Yeon Tae Jeong
    Department of Biological Sciences, KAIST, Daejeon 305 701, Korea
    J Microbiol Biotechnol 18:1945-52. 2008
    ..Thus, coexpression of alpha2,3-ST and beta1,4-GT may be beneficial for producing therapeutic glycoproteins with enhanced sialylation in CHO cells...
  67. ncbi Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysis
    Anne C Kotto-Kome
    Division of Neonatology, Department of Pediatrics, University of South Florida College of Medicine, All Children s Hospital, St Petersburg, FL 33772, USA
    J Perinatol 24:11-5. 2004
    b>Recombinant erythropoietin (rEpo) has been administered to women with postpartum anemia in an attempt to accelerate their increase in hemoglobin concentration and reduce postpartum transfusions...
  68. ncbi Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formation
    Abdullah Kumral
    Department of Pediatrics, School of Medicine, Dokuz Eylul University, Izmir, Turkey
    Biol Neonate 84:325-9. 2003
    ..The aim of this study was to investigate NO formation in an experimental model of NEC and the possible role of NO in the protection Epo provides against NEC...
  69. ncbi Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin
    Todd M Blodgett
    Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Nucl Med 29:161-3. 2004
    ..This case demonstrates the need to consider erythropoietin in the differential diagnosis of possible etiologies causing diffuse bone marrow uptake on PET scans...
  70. ncbi Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes
    Pellegrino Musto
    Unit of Haematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza, S Giovanni Rotondo, Italy
    Br J Haematol 122:269-71. 2003
    Thirteen patients with low-to-intermediate risk myelodysplastic syndrome (MDS) received recombinant erythropoietin (r-EPO) at the single, weekly dose of 40.000 U for at least 8 weeks. Five patients (38...
  71. ncbi Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma
    Elisabeth Kjellen
    Departments of Oncology, Lund University Hospital, Lund
    Acta Otolaryngol 126:545-7. 2006
    ..It could be hypothesized that the effects of rHuEpo on tumour cell growth might only be manifested in vivo and after cell trauma, and that treating anaemia with rHuEpo might contribute to poor outcome after incomplete surgical resection...
  72. ncbi Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients
    Nassim Kamar
    Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France
    Transpl Int 23:277-84. 2010
    ..High doses of ESA within the first month of kidney transplantation have no impact on anemia or renal function by 1 month post-transplant...
  73. ncbi Kinetic and thermodynamic analysis of thermal unfolding of recombinant erythropoietin
    T Arakawa
    Alliance Protein Laboratories, Thousand Oaks, CA 91360, USA
    Biosci Biotechnol Biochem 65:1321-7. 2001
    ..0, the results are similar, i.e., EPO suffered a substantial aggregation, while it showed little aggregation in 20 mm Tris or histidine at pH 7.0 and 20 mm glycine at pH 6.3 under identical heat treatment...
  74. pmc Recombinant erythropoietin and blood transfusion in selected preterm infants
    M P Meyer
    Neonatal Unit, Kidz First, Middlemore Hospital and the University of Auckland, New Zealand
    Arch Dis Child Fetal Neonatal Ed 88:F41-5. 2003
    To comprehensively identify preterm infants likely to require blood transfusion and to investigate the effectiveness of recombinant erythropoietin in this high risk subgroup.
  75. ncbi Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice
    Georg Stüben
    Department of Radiotherapy, West German Tumor Centre, Universitatsklinikum, Essen, Germany
    Int J Radiat Oncol Biol Phys 55:1358-62. 2003
    ..The effect of recombinant human erythropoietin (rhEPO) on the radiosensitivity of human tumor xenografts growing in anemic and nonanemic nude mice was studied...
  76. ncbi Managing the anemia of prematurity: red blood cell transfusions versus recombinant erythropoietin
    R G Strauss
    University of Iowa College of Medicine, Iowa City, Iowa 52242-1182, USA
    Transfus Med Rev 15:213-23. 2001
    ..b>Recombinant erythropoietin therapy has not been widely adopted because it does not consistently reduce the need for red blood cell ..
  77. ncbi Effects of human recombinant erythropoietin on differentiation and distribution of erythroid progenitor cells on murine medullary and splenic erythropoiesis during hypoxia and post-hypoxia
    S M Mide
    Department of Physiology, University of Buenos Aires, School of Dentistry, Buenos Aires, Argentina
    In Vivo 15:125-32. 2001
    ..It is noteworthy that our studies show that the spleen functions as a large reservoir of erythroid precursors for hypoxia-induced stress erythropoiesis...
  78. ncbi Erythropoietin biology in cancer
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
    Clin Cancer Res 12:332-9. 2006
    ..This review describes Epo and EpoR biology, focusing on the pleiotropic effects of Epo on nonhematopoietic tissues as well as the expression and function of EpoR in cancer cells...
  79. ncbi Isolation and characterization of an anti-recombinant erythropoietin single-chain antibody fragment using a phage display antibody library
    Jiebo Mi
    Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P R China
    Anal Bioanal Chem 383:218-23. 2005
    ..The reported method is a very powerful tool to produce specific antibodies for rHuEPO detection demands...
  80. ncbi Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients
    E Movilli
    Division and Chair of Nephrology, Spedali Civili and University of Brescia, Italy
    Nephrol Dial Transplant 16:111-4. 2001
    ..By optimizing rHuEpo responsiveness, an adequate dialysis treatment can contribute to the reduction of the costs of rHuEpo therapy...
  81. ncbi Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro
    Mauro Vairano
    Institute of Pharmacology, Catholic University Medical School, Rome, Italy
    Eur J Neurosci 16:584-92. 2002
    ....
  82. ncbi Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin
    Sandra E Juul
    Department of Pediatrics, University of Washington, Seattle, Wash 98195, USA
    Biol Neonate 85:138-44. 2004
    ..We demonstrate that high-dose rEpo was well tolerated and results in neuroprotective concentrations in spinal fluid of adult and developing animal models by 2-2.5 h after injection...
  83. ncbi Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients
    Aantje V Kharagjitsingh
    Department of Internal Medicine, Medical Center Haaglanden, Westeinde, Den Haag, The Netherlands
    Kidney Int 68:1215-22. 2005
    ..The objectives of this study were to determine the incidence and causes of recombinant EPO hyporesponse, of antibodies to EPO in patients on dialysis, and to relate the detection of anti-EPO antibodies to the presence of PRCA...
  84. ncbi Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin
    Alexandre I Belenkov
    Department of Oncology, Division of Radiation Oncology, Montreal General Hospital, Montreal, Quebec, Canada
    Mol Cancer Ther 3:1525-32. 2004
    ..Our findings indicate that rhEPO result in a significant, JAK2-dependent, in vitro resistance to ionizing radiation and to cisplatin in the human cancer cells lines studied in this report...
  85. ncbi Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model
    Sandra E Juul
    Department of Pediatrics, University of Washington, Seattle, WA 98195 6320, USA
    Dev Neurosci 30:231-42. 2008
    ..we developed a neonatal mouse model of moderate to severe oxidative brain injury and hypothesized that recombinant erythropoietin (rEpo) would decrease the expression of proapoptotic and proinflammatory genes 24 and 48 h, respectively,..
  86. ncbi The importance of anemia and its correction in the management of severe congestive heart failure
    Donald S Silverberg
    Department of Nephrology, Tel Aviv Medical Center, Weizman 6, Tel Aviv 64239, Israel
    Eur J Heart Fail 4:681-6. 2002
    ..This so-called Cardio Renal Anemia Syndrome is very common in CHF. Its successful treatment demands close cooperation between cardiologists and nephrologists...
  87. ncbi Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model
    Kevin K Suk
    Loma Linda University, School of Medicine, Loma Linda, California 92354, USA
    J AAPOS 12:233-8. 2008
    ..We sought to determine whether rhEPO is an independent risk factor for the development of ROP...
  88. ncbi Enhanced sialylation of recombinant erythropoietin in genetically engineered Chinese-hamster ovary cells
    Yeon Tae Jeong
    Department of Biological Sciences, KAIST Korea Advanced Institute of Science and Technology, 335 Gwahangno, Yuseong Gu, Daejeon 305 701, Republic of Korea
    Biotechnol Appl Biochem 52:283-91. 2009
    ..The present study provides a useful strategy for enhancing the sialylation of therapeutic glycoproteins produced in CHO cells...
  89. ncbi Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis
    Maria G Garcia
    The National Institute of Perinatology, Mexico City, Mexico
    J Perinatol 22:108-11. 2002
    Using the approach of a meta-analysis, we sought to determine whether the administration of recombinant erythropoietin (rEpo) to very low birth weight (VLBW) infants, after the first week of life, results in fewer "late" ..
  90. ncbi Recombinant human erythropoietin in preoperative autologous blood donation did not influence the haemoglobin recovery after surgery
    A Avall
    Department of Anesthesia and Intensive Care, East Hospital, Goteborg, Sweden
    Acta Anaesthesiol Scand 47:687-92. 2003
    ..The aim of the study was to determine endogenous erythropoietin production and haemoglobin recovery after preoperative autologous blood donation and surgery, with or without recombinant human erythropoietin treatment...
  91. ncbi Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity
    Mark S Brown
    Department of Pediatrics, Presbyterian St Luke s Medical Center, and Department of Preventive Medicine and Biometrics, University of Colorado School of Medicine, Denver, Colorado 80218, USA
    J AAPOS 10:143-9. 2006
    ..in a regional referral hospital changed substantially during 1995 to 1998 and presented us with an opportunity to examine whether there was a protective effect on risk of retinopathy associated with exposure to recombinant erythropoietin.
  92. ncbi Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo
    D Ribatti
    Institute of Human Anatomy, Histology and Embryology, Department of Biomedical Sciences and Human Oncology, University of Bari School of Medicine, Bari, Italy
    Blood 93:2627-36. 1999
    ..Taken together, these data demonstrate the ability of Epo to interact directly with endothelial cells and to elicit an angiogenic response in vitro and in vivo and thus act as a bona fide direct angiogenic factor...
  93. ncbi Iron deficiency and erythropoiesis: new diagnostic approaches
    Carlo Brugnara
    Children s Hospital Boston, Department of Laboratory Medicine, 300 Longwood Ave, Boston, MA 02115, USA
    Clin Chem 49:1573-8. 2003
    ..The combination of hematologic markers such as reticulocyte hemoglobin content, which decreases with iron deficiency, and R/F ratio may allow for a more precise classification of anemias...
  94. ncbi Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats
    Lei Wang
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, Mich, USA
    Stroke 35:1732-7. 2004
    ..Erythropoietin (EPO) promotes proliferation and differentiation of erythroid progenitors and the survival of maturing erythroid cells. Here, we investigated the role of EPO in brain repair after stroke...
  95. ncbi Molecular biology of erythropoietin
    Wolfgang Jelkmann
    Institute of Physiology, University of Luebeck, Luebeck, Germany
    Intern Med 43:649-59. 2004
    ..Whether the recent demonstration of EPO receptors in various non-hemopoietic tissues, including tumor cells, is welcome or ominous still needs to be clarified. Evidence suggests that rHuEPO may be a useful neuroprotective agent...
  96. ncbi Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm
    Anantha Vijay R Santhanam
    Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Stroke 36:2731-7. 2005
    ..study, the effect of subarachnoid hemorrhage (SAH) on the phosphorylation of endothelial NO synthase (eNOS) and the ability of recombinant erythropoietin (Epo) to augment this vasodilator mechanism in the spastic arteries were studied.
  97. pmc Erythropoietin both protects from and reverses experimental diabetic neuropathy
    Roberto Bianchi
    Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy
    Proc Natl Acad Sci U S A 101:823-8. 2004
    ..These observations suggest that administration of rhEPO or its analogues may be useful in the treatment of diabetic neuropathy...
  98. ncbi Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models
    Kenneth R LaMontagne
    Drug Discovery, Growth Factors, Johnson and Johnson Pharmaceutical Research and Development, Room B354, OMP Building, 1000 Route 202, PO Box 300, Raritan, NJ 08869, USA
    Mol Cancer Ther 5:347-55. 2006
    ..These results show that recombinant epoetins do not evoke a physiologic response on EPOR-bearing tumor cells as assessed by numerous variables, including growth, migration, and cytotoxic challenge in preclinical in vivo tumor models...
  99. ncbi Erythropoietin and renoprotection
    Ferdinand H Bahlmann
    Department of Internal Medicine IV, Saarland University Medical Centre, Homburg Saar, Germany
    Curr Opin Nephrol Hypertens 18:15-20. 2009
    ..Finally, we will review the current literature on clinical studies with rHuEPO or analogous substances and progression of chronic kidney disease, and propose possible clinical renoprotective strategies...
  100. ncbi Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    J Natl Cancer Inst 98:708-14. 2006
    ..08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events...
  101. ncbi September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents
    Matti S Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Oncologist 13:33-6. 2008
    ..A sustained hemoglobin level of about 12 g/dl should be the target for treatment with ESAs. ESAs should be used according to the EORTC guidelines and within label with carefully considered exceptions...

Research Grants57

  1. Long-acting EPO analog for treating anemia associated with chronic kidney disease
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Recombinant erythropoietin (EPO) is widely used to ameliorate anemia in patients with chronic kidney disease, which affects 20- 40 ..
  2. Brain imaging and developmental follow-up of infants treated with erythropoietin
    Robin K Ohls; Fiscal Year: 2013
    ..One promising intervention is the use of recombinant erythropoietin (Epo, also known as an erythropoiesis stimulating agent, or ESA)...
  3. Preterm Epo Neuroprotection Trial (PENUT Trial) CCC
    Sandra E Juul; Fiscal Year: 2013
    ..New approaches are needed to improve these outcomes. Recombinant erythropoietin (Epo) is a promising novel neuroprotective agent...
  4. Preterm Epo Neuroprotection Trial (PENUT Trial) DCC
    Patrick J Heagerty; Fiscal Year: 2013
    ..New approaches are needed to improve these outcomes. Recombinant erythropoietin (Epo) is a promising novel neuroprotective agent...
  5. BMP4 dependent stress erythropoiesis pathway in short-term radioprotection
    ROBERT FRANK PAULSON; Fiscal Year: 2013
    ..work, however, suggests that the primary therapies for anemia, transfusion therapy and treatment with recombinant erythropoietin (Epo), can themselves cause pathology...
  6. Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome
    Alan F List; Fiscal Year: 2012
    ..therapeutic challenge in MDS with only a minority of patients experiencing sustained benefit from recombinant erythropoietin (EPO)...
  7. RADIOASSAY OF ERYTHROPOIETIN
    GISELA CLEMONS; Fiscal Year: 1991
    ..These studies may be of future clinical value in treatment of the anemia in premature infants with recombinant erythropoietin. Other animal studies are concerned with the effect of other hormones on renal erythropoietin synthesis ..
  8. Epo Neuroprotection of ELBW Infants: Planning Grant
    Sandra E Juul; Fiscal Year: 2010
    ..a detailed research plan in order to carry out a multicenter randomized controlled trial of high dose recombinant erythropoietin (rEpo) as an early intervention to improve long-term neurological outcomes in extremely low birth weight ..
  9. A NOVEL ELECTROPORATION SYSTEM FOR GENE THERAPY WITH EPO
    MAIDA DE LAS ALAS; Fiscal Year: 2002
    ..Anemia is currently treated with repeated administration of recombinant erythropoietin (EPO), which is expensive and not readily available to these patients due to the already elevated cost ..
  10. CLINICAL MODEL OF ERYTHROPOIETIN GENE THERAPY
    William Osborne; Fiscal Year: 1999
    ..In the USA the estimated annual cost of recombinant erythropoietin for the 85,000 patients with anemia of chronic renal failure is about $500 million...
  11. Epo as a Rescue Agent for Perinatal Hypoxia-Ischemia
    Sandra Juul; Fiscal Year: 2004
    ....
  12. Nonhematopoietic Developmental Functions of EPO
    Sandra Juul; Fiscal Year: 2004
    ..We feel these experiments will provide important specific insights into the regulation of neonatal intestinal growth and injury. ..
  13. Antiestrogenic Effects on Tumor Angiogenesis
    Kimberly Blackwell; Fiscal Year: 2006
    ..The results of this project will have profound implications, especially as clinicians begin to use the newer estrogen receptor modulating drugs for the prevention and treatment of breast cancer. ..
  14. Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  15. Nutritional/Inflammatory Evaluation of Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2005
    ....
  16. Inner-City Nephrology
    Onyekachi Ifudu; Fiscal Year: 2002
    ..abstract_text> ..
  17. Erythropoietin receptors in breast cancer
    MURAT ARCASOY; Fiscal Year: 2008
    ..abstract_text> ..
  18. 2006 Cancer Model Mechanisms
    William Kaelin; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  19. Erythropoiesis & pulse arginine butyrate in sickle cell
    Susan Perrine; Fiscal Year: 2005
    ..Abstract Not Provided ..
  20. Physician Training Program in Neonatal Biology
    John Widness; Fiscal Year: 2007
    ..With NIH support beyond that which the investigators currently enjoy, the investigators will be able to significantly enhance the research training experiences they offer their postdoctoral physician trainees in neonatal medicine. ..
  21. Best Practices in Transfusion Medicine for Patients with Sickle Cell Disease
    Theodore Wun; Fiscal Year: 2007
    ..Use of these pathways will improve the care for these patients. (End of Abstract) [unreadable] [unreadable] [unreadable]..
  22. Temporal lobe epilepsy - validation of a new animal model
    Tore Eid; Fiscal Year: 2008
    ..More effective therapies of epilepsy are therfore needed. This proposal seeks to validate a new animal model that may greatly speed up the search for better therapies against this disorder. ..
  23. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  24. PULMONARY ENDOTHELIAL FUNCTION DURING CHRONIC HYPOXIA
    Benjimen Walker; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  25. A Luciferase Fusion Protein Library to Identify & Monitor Ubiquitylation Targets
    William Kaelin; Fiscal Year: 2008
    ..Reisolation of HIF in aims 2 and 3 would constitute proof of concept with respect to the potential utility of this approach. ..
  26. TREATMENT OF TRAUMATIC BRAIN INJURY WITH SIMVASTATIN
    Asim Mahmood; Fiscal Year: 2009
    ..abstract_text> ..
  27. TRAUMATIC BRAIN INJURY AND MARROW STROMAL CELLS
    Asim Mahmood; Fiscal Year: 2009
    ..If the treatment combining MSCs with simvastatin is found to be more effective than monotherapy, this will increase the clinical relevance of MSC treatment by allowing us to use smaller and safer doses. ..
  28. Mechanisms of adhesion and growth control in stem cells
    Reuben Kapur; Fiscal Year: 2008
    ..Our proposed studies will provide unique insights into the physiologic significance of the in vivo interactions between class IA PI3K, PTEN and ROCK1 in regulating growth and survival in SC/Ps. ..
  29. Oral Therapeutic for Beta-Thalassemia
    Susan Perrine; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  30. Evaluation of the Quality of Clinical Trials
    Benjamin Djulbegovic; Fiscal Year: 2006
    ..It is also hoped that public confidence in COG research may further increase, which in turn will enable development of more rapid advances in the war against cancer. ..
  31. Real-Time Imaging of Hypoxia based on VHL Activity
    William Kaelin; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  32. CANCER AND LEUKEMIA GROUP B
    MARGARET KESSINGER; Fiscal Year: 2002
    ..During the coming grant period, UNMC will continue to make major contributions to group accrual, group science and group administration. Additional financial support will facilitate and strengthen these contributions. ..
  33. Mechanisms of adhesion and growth control in stem cells
    Reuben Kapur; Fiscal Year: 2010
    ..Our proposed studies will provide unique insights into the physiologic significance of the in vivo interactions between class IA PI3K and phosphatases in regulating growth and survival in SC/Ps. ..
  34. FETAL GLOBIN INDUCTION IN BETA THALASSEMIA
    Susan Perrine; Fiscal Year: 2002
    ..These studies should determine the proportion and some genotypes of beta thalassemia patients which can benefit from Pulsed Butyrate plus/minus rhu-EP0 therapy. ..
  35. NCI TRANSITION CAREER DEVELOPMENT AWARD
    Theresa Gillespie; Fiscal Year: 2003
    ....
  36. A QTL for fetal hemoglobin and F cells on chromosome 8q
    Swee Thein; Fiscal Year: 2003
    ..The discovery of these factors may also suggest new approaches for therapeutic augmentation of fetal hemoglobin production in patients with SCD and beta thalassemia. ..
  37. Equipoise and the research integrity of clinical trials
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..This proposal will answer both the question "what do trials do for us?" and assess the reliability of the research in which public has invested so much. ..
  38. Postoperative Cognitive Dysfunction in the Elderly
    Terri Monk; Fiscal Year: 2004
    ..Given the breadth of my proposed training program, I will be able to interact with and serve as a mentor for anesthesiologists and also the broader corpus of scientists, both clinical and basic, interested in aging and neuroscience. ..
  39. Vascular Role of Carbon Monoxide during Chronic Hypoxia
    Benjimen Walker; Fiscal Year: 2004
    ..The proposed experiments utilize a variety of in vivo and in vitro approaches to examine questions central to the regulation of the systemic circulation by a novel vasodilatory pathway under clinically relevant conditions. ..
  40. NO AND EXERCISE VASODILATION IN HUMAN HYPERLIPIDEMIA
    Michael Joyner; Fiscal Year: 2004
    ..Data from these patient- oriented studies have implications related to understanding the contribution of endothelial function in a variety of common diseases. ..
  41. Herpes Simplex Virus, Early Brain Injury and Epilepsy
    Tore Eid; Fiscal Year: 2004
    ..If a viral causation of TLE is established, then this would not only open new avenues for prevention and control of this disorder, but also improve our understanding of viral-induced brain injury. ..
  42. Epo-dependent JAK2 Signaling in Painful Neuropathy
    WENDY CAMPANA; Fiscal Year: 2006
    ..The experiments will provide new information on the basic mechanisms of nerve injury and pain, and there from, new rationale for development of novel neuroprotective strategies for preventing chronic neuropathic pain. ..
  43. MECHANISMS OF HYPOALBUMINEMIA IN ENDSTAGE RENAL DISEASE
    George Kaysen; Fiscal Year: 2001
    ..We will further establish the effect of KT/V, dialyzer permeability and reuse on changes in albumin, nutritional status and acute phase response. ..
  44. Using Synthetic Lethality to Select Cancer Drug Targets
    William Kaelin; Fiscal Year: 2005
    ..Moreover, they may establish a new paradigm for the selection of anticancer drug targets based on inactivating mutations of TSG. ..
  45. MECHANISM OF RETINAL ISCHEMIA
    DANIEL ROSENBAUM; Fiscal Year: 2005
    ..b) Multi-modal therapy employing caspase inhibitor(s) and anti-excitotoxic strategies work synergistically toreduce ischemic retinal damage. ..
  46. Pharmacophore-Modeled Screening for HbF-Inducing Agents
    Susan Perrine; Fiscal Year: 2004
    ..virtual screening using molecular modeling with confirmation by reporter assay and selection of a specific HDAC activity should generate additional compounds for development of an optimal HbF inducer for an effective life-long treatment ..
  47. 2008 AUA/SBUR Summer Research Conference
    Arthur Burnett; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  48. Osteoporosis Prevention in Early Stage Breast Cancer
    Dawn Hershman; Fiscal Year: 2006
    ..abstract_text> ..
  49. NITRIC OXIDE REGULATORY SYSTEM IN THE PENIS
    Arthur Burnett; Fiscal Year: 2002
    ....
  50. Simvastatin treatment of experimental intracerebral hemorrhage
    DONALD M SEYFRIED; Fiscal Year: 2010
    ....
  51. Proteomic Analysis of Retinal Ganglion Cell Death in Glaucoma
    GULGUN TEZEL; Fiscal Year: 2010
    ..These studies are expected to provide comprehensive information about the nerve cell death process, thereby allowing new treatment possibilities for 3 million Americans suffering from glaucoma. ..
  52. CENTER FOR STROKE RESEARCH
    Michael Chopp; Fiscal Year: 2007
    ..Our studies are designed to improve neurological function and the management of the stroke patient. ..
  53. Treatment of Neural Injury with MSCs
    Michael Chopp; Fiscal Year: 2007
    ..The long-term goal of this Program Project application is to translate our finding of therapeutic benefit after treatment of experimental stroke and traumatic brain injury with MSCs to the patient. ..
  54. ANTIICAM-1 AND RTPA TREATMENT OF EMBOLIC STROKE
    Michael Chopp; Fiscal Year: 2002
    ..This technology and the proposed experiments will enhance our understanding of the mechanisms underlying microvascular dysfunction and occlusion after stroke and thrombolytic treatment. ..
  55. Estrogen and the Aging Blood Brain Barrier
    OAK CHI; Fiscal Year: 2002
    ..The information obtained from our study will be crucially important for the clinical application of estrogen therapy for stroke as well as understanding the pathophysiology of age related cerebrovascular changes. ..
  56. Intervention for Colorectal Cancer
    Charles Bennett; Fiscal Year: 2003
    ..The proposed interventions will improve the standard Veterans Affairs colorectal cancer screening protocol and will provide a model for methods and materials to increase screening rates in other settings. ..